Clinical features and prognostic factors for patients with bone metastases from prostate cancer. 2012

Jian He, and Zhao-Chong Zeng, and Ping Yang, and Bing Chen, and We Jiang, and Shi-Suo Du
Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. hejian62@163.com

To identify the clinical features and independent predictors of survival in patients with bone metastases from prostate cancer (PCa). We retrospectively analysed 115 PCa patients with bone metastases between 1997 and 2009. The overall survival rate after bone metastases was calculated using the Kaplan-Meier method. The prognostic factors were identified by univariate analysis using a log-rank test and by multivariate analysis using Cox proportional hazards regression models. The follow-up rate was 100%, the follow-up cases during 1, 3 and 5 years were 103, 79 and 55, respectively. The 1-, 3- and 5-year survival rates were 89.1%, 60.9% and 49.8%, respectively, with a median survival time of 48.5 months for patients with bone metastases from PCa. In univariate analysis, age, Gleason score, clinical stage, the number of bone lesions, alkaline phosphatase (ALP) level, invasion of neighbouring organs and non-regional lymph node metastases were correlated with prognosis. By multivariate analysis using Cox regression, ALP level, Gleason score and non-regional lymph node metastases were independent prognostic factors. These prognostic factors will help us to determine the appropriate dose and fraction of radiotherapy for these patients.

UI MeSH Term Description Entries
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D002681 China A country spanning from central Asia to the Pacific Ocean. Inner Mongolia,Manchuria,People's Republic of China,Sinkiang,Mainland China
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Jian He, and Zhao-Chong Zeng, and Ping Yang, and Bing Chen, and We Jiang, and Shi-Suo Du
July 2013, Surgery today,
Jian He, and Zhao-Chong Zeng, and Ping Yang, and Bing Chen, and We Jiang, and Shi-Suo Du
May 2020, The Journal of international medical research,
Jian He, and Zhao-Chong Zeng, and Ping Yang, and Bing Chen, and We Jiang, and Shi-Suo Du
October 2017, Hepatobiliary & pancreatic diseases international : HBPD INT,
Jian He, and Zhao-Chong Zeng, and Ping Yang, and Bing Chen, and We Jiang, and Shi-Suo Du
February 2020, Translational cancer research,
Jian He, and Zhao-Chong Zeng, and Ping Yang, and Bing Chen, and We Jiang, and Shi-Suo Du
May 2024, Journal of chemotherapy (Florence, Italy),
Jian He, and Zhao-Chong Zeng, and Ping Yang, and Bing Chen, and We Jiang, and Shi-Suo Du
November 2013, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Jian He, and Zhao-Chong Zeng, and Ping Yang, and Bing Chen, and We Jiang, and Shi-Suo Du
August 2017, Medical science monitor : international medical journal of experimental and clinical research,
Jian He, and Zhao-Chong Zeng, and Ping Yang, and Bing Chen, and We Jiang, and Shi-Suo Du
January 2014, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Jian He, and Zhao-Chong Zeng, and Ping Yang, and Bing Chen, and We Jiang, and Shi-Suo Du
January 2020, Oncology letters,
Jian He, and Zhao-Chong Zeng, and Ping Yang, and Bing Chen, and We Jiang, and Shi-Suo Du
January 1999, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica,
Copied contents to your clipboard!